✨ Free AI Report
Bachem Holding AG: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Bachem Holding AG
Company Research

Bachem Holding AG: Business Overview, Financials & Competitive Analysis

Bachem Holding AG scores 8/10 on the AskCyborg Cyborg Score (Strong). Leading peptide CDMO with structural market tailwinds, aggressive capacity expansion, and consistent execution targeting >CHF 1B revenue by 2026. Bachem increased sales in Swiss francs by 4.8% to CHF 605.3 million in 2024, with sales increasing by 5.6% in local currencies. Operating EBITDA increased by 5.7% to CHF 176.3.

What is Bachem Holding AG's industry? Bachem Holding AG (bachem.com) operates in Pharmaceutical Contract Development and Manufacturing (CDMO) - Peptides & Oligonucleotides. AskCyborg classifies Bachem Holding AG under Pharmaceutical Contract Development and Manufacturing (CDMO) - Peptides & Oligonucleotides in its company registry.

Bachem specializes in the development and manufacture of peptides and oligonucleotides, providing products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies. ...

8/ 10Strong

Cyborg Score thesis

Leading peptide CDMO with structural market tailwinds, aggressive capacity expansion, and consistent execution targeting >CHF 1B...

Read the full analyst-debate transcript →
Industry Pharmaceutical Contract Development and Manufacturing (CDMO) - Peptides & Oligonucleotides
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 28, 2026
AI-Verified Research
30+ Page Report

Get the Latest Bachem Holding AG Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Bachem Holding AG

AskCyborg analysts argue the bull and bear cases for Bachem Holding AG across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Bachem Holding AG OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Bachem Holding AG Overview

Pro stress-test →

Bachem specializes in the development and manufacture of peptides and oligonucleotides, providing products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies. The company operates a critical CDMO (contract development and manufacturing organization) role in the biotech supply chain, serving a growing market demand for peptide-based therapeutics.

Strategic Profile

Pro stress-test →

Bachem is building new capacity to manufacture peptides at ton-scale for medicines in urgent demand. The company aims for annual sales of more than CHF 1 billion and an EBITDA margin of over 30% in 2026. With strong organic growth and aggressive capacity expansion, Bachem is positioned as the leading peptide CDMO in a high-growth market segment.

Competitive Landscape

Pro stress-test →

Lonza Group is identified as one of Bachem's main competitors. Bachem competes in the specialized CDMO market focused on peptides and oligonucleotides. The market is consolidating around specialized providers, where Bachem holds a leading position due to its peptide manufacturing scale and capabilities.

Industry Context

Bachem Holding AG operates in Pharmaceutical Contract Development and Manufacturing (CDMO) - Peptides & Oligonucleotides.

Key facts

Founded: 1971 · Headquarters: Bubendorf, Switzerland · Employees: 2,200 · Revenue: $781M · Market cap: $4.58B

What the analysts stress-tested

The top findings that survived the multi-agent debate for Bachem Holding AG.

  • Commercial API sales reached CHF 327.0 million with a strong increase in patent-protected peptide sales.
  • For 2025, Bachem expects growth between 10-15% in local currencies with EBITDA margins in the high twenties.
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • July 2025Full-year 2024 results: CHF 605.3M revenue (+4.8%), EBITDA CHF 176.3M (+5.7%), targeting CHF 1B+ sales by 2026
  • 2024Major CAPEX investment of CHF 292.2M with continued capacity expansion at all sites
  • +1 moreTrack every material event for Bachem Holding AG as it happens. Explore monitoring →
Get alerted when Bachem Holding AG has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

LonzaIntegrated CDMO with peptide and oligonucleotide capabilities→FerringPeptide development and manufacturing services→DipexiumSpecialty pharmaceutical CDMO→

Compare Bachem Holding AG with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Bachem Holding AG operates in Pharmaceutical Contract Development and Manufacturing (CDMO) - Peptides & Oligonucleotides. See how the rest of the sector scores on the Cyborg framework.

Browse Pharmaceutical Contract Development and Manufacturing (CDMO) - Peptides & Oligonucleotides research →
NEW · MCP server

Ask your AI assistant about Bachem Holding AG

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Bachem Holding AG and its top competitor on Cyborg Score”
“What did Bachem Holding AG do this quarter?”
“Is Bachem Holding AG a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Bachem Holding AG do?+
Bachem specializes in the development and manufacture of peptides and oligonucleotides, providing products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies. ...
What is Bachem Holding AG's Cyborg Score?+
Bachem Holding AG has a Cyborg Score of 8/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Bachem Holding AG's main competitors?+
Named competitors include Lonza, Ferring, Dipexium. The full competitive landscape is in the AskCyborg report.
How can I get the full Bachem Holding AG research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Bachem Holding AG research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Bachem Holding AG over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Pharmaceutical Contract Development and Manufacturing (CDMO) - Peptides & Oligonucleotides research

Companies in the same sector and named competitors, ranked by Cyborg Score.

8Lonza Group AG